Oura has confidentially submitted a draft registration statement with the SEC for a proposed initial public offering. The number of shares and price range have not been determined, with the IPO expected after the SEC completes its review process, subject to market conditions.
The filing comes during the most aggressive women’s health expansion in Oura’s history. In just the past few weeks, the company has launched hormonal birth control support and menopause insights features, released a proprietary women’s health AI model, acquired Galen AI to integrate clinical data with wearable biometrics, and partnered with Natural Cycles for fertility tracking. Women are now the majority of Oura’s new members, and the company has partnered with Maven, Progyny, and Twentyeight Health to connect wearable data to clinical care.
Oura tracks 50+ health metrics for millions of members worldwide and has over 1,200 partners across wellness and medicine. The company was founded in Finland in 2013 and is headquartered in San Francisco.
